Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on enGene Holdings (ENGN – Research Report) and keeping the price target at $25.00.
Andres Y. Maldonado has given his Buy rating due to a combination of factors surrounding enGene Holdings’ promising lead candidate, detalimogene voraplasmid. The drug is currently in the pivotal LEGEND study for high-risk non-muscle invasive bladder cancer, showing a promising clinical profile with a 71% complete response rate at any time and a 47% rate at six months. These results are favorable compared to recent approvals, suggesting a strong path to regulatory approval.
Additionally, the projected complete response rates and the straightforward administration of detalimogene offer competitive advantages over existing therapies. The safety profile is expected to remain consistent, with no unexpected adverse findings anticipated. Furthermore, recent protocol amendments in the LEGEND study aim to enhance data comparability and improve clinical practices, potentially boosting investor confidence as more data becomes available.
According to TipRanks, Y. Maldonado is a 2-star analyst with an average return of 1.1% and a 34.18% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as Corbus Pharmaceuticals, ImmunityBio, and Scholar Rock Holding.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $34.00 price target.